PT799046E - Solucoes estaveis de 2-cloro-2'-desoxiadenosina - Google Patents

Solucoes estaveis de 2-cloro-2'-desoxiadenosina

Info

Publication number
PT799046E
PT799046E PT95943101T PT95943101T PT799046E PT 799046 E PT799046 E PT 799046E PT 95943101 T PT95943101 T PT 95943101T PT 95943101 T PT95943101 T PT 95943101T PT 799046 E PT799046 E PT 799046E
Authority
PT
Portugal
Prior art keywords
deoxyadenosin
chloro
stable solutions
cda
cresol
Prior art date
Application number
PT95943101T
Other languages
English (en)
Inventor
Michael Bornstein
Rosemary Rozman
Kevin Francis Long
Hsiao Yung Guh
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of PT799046E publication Critical patent/PT799046E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
PT95943101T 1994-12-21 1995-12-15 Solucoes estaveis de 2-cloro-2'-desoxiadenosina PT799046E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/362,106 US5641757A (en) 1994-12-21 1994-12-21 Stable 2-chloro-2'-deoxyadenosine formulations

Publications (1)

Publication Number Publication Date
PT799046E true PT799046E (pt) 2002-10-31

Family

ID=23424722

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95943101T PT799046E (pt) 1994-12-21 1995-12-15 Solucoes estaveis de 2-cloro-2'-desoxiadenosina

Country Status (16)

Country Link
US (1) US5641757A (pt)
EP (1) EP0799046B1 (pt)
JP (1) JP2001520627A (pt)
AT (1) ATE218351T1 (pt)
AU (1) AU709785B2 (pt)
CZ (1) CZ194197A3 (pt)
DE (1) DE69526970T2 (pt)
DK (1) DK0799046T3 (pt)
ES (1) ES2177677T3 (pt)
HU (1) HU220628B1 (pt)
IL (1) IL116468A0 (pt)
PL (1) PL320918A1 (pt)
PT (1) PT799046E (pt)
SI (1) SI0799046T1 (pt)
WO (1) WO1996019229A1 (pt)
ZA (1) ZA9510865B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
EP1827461B1 (en) 2004-12-22 2012-02-29 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10849919B2 (en) 2017-11-24 2020-12-01 Merck Patent Gmbh Cladribine regimen for treating progressive forms of multiple sclerosis
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
CA3209648A1 (en) 2021-03-03 2022-09-09 Ursula BOSCHERT SHAFAATIAN Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO1993023058A1 (en) * 1992-05-19 1993-11-25 The Scripps Research Institute Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia

Also Published As

Publication number Publication date
AU4422996A (en) 1996-07-10
WO1996019229A1 (en) 1996-06-27
PL320918A1 (en) 1997-11-10
DE69526970D1 (de) 2002-07-11
CZ194197A3 (en) 1997-10-15
ES2177677T3 (es) 2002-12-16
HU220628B1 (hu) 2002-03-28
DE69526970T2 (de) 2003-01-09
ATE218351T1 (de) 2002-06-15
SI0799046T1 (en) 2002-10-31
AU709785B2 (en) 1999-09-09
DK0799046T3 (da) 2002-09-16
MX9704731A (es) 1997-10-31
JP2001520627A (ja) 2001-10-30
HUP9900774A2 (en) 2001-05-28
US5641757A (en) 1997-06-24
EP0799046A1 (en) 1997-10-08
ZA9510865B (en) 1997-06-20
IL116468A0 (en) 1996-03-31
EP0799046B1 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
PT799046E (pt) Solucoes estaveis de 2-cloro-2'-desoxiadenosina
MY121360A (en) Clear cleansing detergent systems.
BR0109943A (pt) Composições farmacêuticas
ITTO950085V0 (it) "raccordo luer-lock con cappuccio di protezione per linee medicali di infusione-trasfusione."
IT1285180B1 (it) Sistema di comunicazione in grado di prevedere le buone opportunita' di comunicazione.
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
MY131095A (en) Polyethylene protein conjugates.
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
CA2338754A1 (en) Cosmetic composition
BR9707689A (pt) Caramelos contendo um agente adoçante
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
HK1029290A1 (en) Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
DE69711649D1 (de) P1, p4-dithio-p2,p3-monochloromethylen 5',5'''-diadenosin-p1,p4-tetraphosphat verwendet als anti-thrombose mittel
PT801571E (pt) Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
RU95119203A (ru) Иммуномодулирующее средство
ES2178200T3 (es) Conservante para lentes de contacto, solido y soluble en agua.
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
IT1303684B1 (it) Formulazioni di apomorfina in soluzione stabili nel tempo.
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
IT1292763B1 (it) Involucro sterile per la protezione di apparecchi medicali durante l'uso.
RU96103721A (ru) Антгельминтное средство